964-78-3Relevant academic research and scientific papers
Colorimetric chemosensor for multiple targets, Cu2+, CN- and S2-
Ryu, Ka Young,Lee, Jae Jun,Kim, Jin Ah,Park, Dae Yul,Kim, Cheal
, p. 16586 - 16597 (2016)
A simple and easily synthesized colorimetric chemosensor 1, (E)-2-(((2-((2,4-dinitrophenyl)amino)phenyl)imino)methyl)phenol, was designed and synthesized for the detection of Cu2+, CN- and S2-. Receptor 1 showed a highly selective colorimetric response to copper(ii) ions by changing its color from pale yellow to orange immediately without any interference from other metal ions. Also, the sensitivity of UV-vis based assay (8.77 μM) for Cu2+ is below the World Health Organization (WHO) guidelines for drinking water (31.5 μM). In addition, chemosensor 1 could be used to quantify Cu2+ in water samples and the sensing mechanism of the 1-Cu2+ complex was explained by theoretical calculations. The 1-Cu2+ complex could be reversible simply through treatment with an appropriate reagent such as EDTA. Moreover, with the "naked eye" 1 could sense cyanide and sulfide by color changes from pale yellow to pale pink and deep pink, respectively, in aqueous solution. Furthermore, sensor 1 can detect both CN- (0.28 μM) and S2- (10.7 μM) below the given guidelines (WHO: 1.9 μM for CN- and Environmental Protection Agency: 7.8 mM for S2-).
Mixed-valence di-ruthenium(ii,iii) complexes of redox non-innocentN-aryl-o-phenylenediamine derivatives
Dutta, Debarpan,Ghosh, Prasanta,Kundu, Suman,Maity, Suvendu
, p. 7791 - 7803 (2021/06/16)
A mononuclear ruthenium(ii), [(L1IQ)Ru2+(PPh3)2Cl2]·CHCl3(1·CHCl3), a di-ruthenium(ii,ii), [(L2IQ)2Ru24+Cl4
Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer
Tokay, Esra,Güng?r, Tu?ba,Hac?o?lu, Nelin,?nder, Ferah C?mert,Gülhan, ünzile Güven,Tok, Tu?ba Ta?k?n,?elik, Ayhan,Ay, Mehmet,K??kar, Feray
, (2019/12/24)
Prodrugs for targeted tumor therapies have been extensively studied in recent years due to not only maximising therapeutic effects on tumor cells but also reducing or eliminating serious side effects on healthy cells. This strategy uses prodrugs which are safe for normal cells and form toxic metabolites (drugs) after selective reduction by enzymes in tumor tissues. In this study, prodrug candidates (1-36) containing nitro were designed, synthesized and characterized within the scope of chemical experiments. Drug-likeness properties of prodrug candidates were analyzed using DS 2018 to investigate undesired toxicity effects. In vitro cytotoxic effects of prodrug canditates were performed with MTT assay for human hepatoma cells (Hep3B) and prostate cancer cells (PC3) and human umbilical vein endothelial cells (HUVEC) as healthy control. Non-toxic compounds (3, 5, 7, 10, 12, 15, 17, 19 and 21–23), and also compounds (1, 2, 5, 6, 9, 11, 14, 16, 20 and 24) which had low toxic effects, were selected to examine their suitability as prodrug canditates. The reduction profiles and kinetic studies of prodrug/Ssap-NtrB combinations were performed with biochemical analyses. Then, selected prodrug/Ssap-NtrB combinations were applied to prostate cancer cells to determine toxicity. The results of theoretical, in vitro cytotoxic and biochemical studies suggest 14/Ssap-NtrB, 22/Ssap-NtrB and 24/Ssap-NtrB may be potential prodrug/enzyme combinations for nitroreductase (Ntr)-based prostate cancer therapy.
